Jeffrey W. Albers - Aug 26, 2024 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Aug 26, 2024
Transactions value $
-$193,809
Form type
4
Date filed
8/26/2024, 06:31 PM
Previous filing
Jun 20, 2024
Next filing
Sep 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $51.7K +5K $10.34 5K Aug 26, 2024 Direct F1
transaction KYMR Common Stock Sale -$246K -5K -100% $49.10 0 Aug 26, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Options Exercise $0 -5K -30.58% $0.00 11.3K Aug 26, 2024 Common Stock 5K $10.34 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 22, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following the vesting commencement date of July 28, 2020, subject to the reporting person's continued service relationship through each vesting date.